Table 9.
Ongoing and completed clinical trials for peritoneal carcinomatosis - therapeutic intent.
| Therapeutic Intent Trial Title | Status | Interventions | Locations |
|---|---|---|---|
| HIPEC and Systemic Chemotherapy in Unresectable Peritoneal Metastases From Colorectal Cancer | Recruiting | Single Arm: HIPEC with Raltitrexed followed by systemic (Oxaliplatin and Capecitabine) then second look surgery with possible cytoreduction | China |
| HIPEC Using High Intra-abdominal Pressure | Completed | HIPEC with cisplatin | Italy |
| Immunotoxin in Peritoneal Carcinomatosis-ImmunoPeCa Trial | Completed | Arm 1: Low intra-abdominal pressure 8–12mmHg | Norway |
| ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis | Recruiting | Arm 2: High intra-abdominal pressure 18–22mmHg” | United States |
| Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis | Recruiting | Single arm: Cytoreduction and HIPEC followed by MOC31PE Immunotoxin (targeting EpCAM positive cells) | United States |
| The Influence of Perioperative Administration of Dexmedetomidine on Inflammation Response and Postoperative Outcomes in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive Surgery; Double Blind Randomized Controlled Trial | Recruiting | Arm 1: Cytoreduction then HIPEC with Mitomycin C | South Korea |
| Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer | Completed | Arm 2: Cytoreduction then EPIC with FUDR and Leucovorin | United States |
| CAIRO6 trial: Perioperative Systemic Therapy and Surgery Versus Surgery Alone for Resectable Colorectal Peritoneal Metastases. | Recruiting | Arm 1: Cytoreduction then HIPEC with Mitomycin C | Netherlands |
| PRODIGE 7: A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC) | Completed | Arm 2: Cytoreduction then HIPEC with Melphalan | France |
| Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer | Recruiting | Both arms get Cytoreduction then HIPEC. | Austria |
Note: FUDR, floxuridine